Kevin L. Duffin

机构：Eli Lilly (United States) · ORCID：0000-0002-1656-8982

发表论文 220 篇 · 总被引 9959 次 · h-index 52

代表论文

• An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) (2024 · Nature Metabolism · 被引 261)
• Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis (2023 · ˜The œLancet. Gastroenterology & hepatology · 被引 205)
• Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis (2023 · Diabetes Care · 被引 48)
• Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine (2024 · Kidney International · 被引 38)
• Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes (2025 · Cardiovascular Diabetology · 被引 25)
• The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025 · Kidney International Reports · 被引 19)